A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012) Read more
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE Read more
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer Read more
Impact of Bendamustine as an Alternative Lymphodepletion Regimen on Chimeric Antigen Receptor T-Cell Therapy Outcomes Read more
A Phase II Parallel Arm Study of Sacituzumab Govitecan-hziy in Patients with Advanced Thymoma and Thymic Carcinoma Read more
This protocol is for the use of CliniMACS CD34 Reagent System in a single patient with relapsed AML. Patient received salvage chemo and planned stem cell boost for cytopenias. Since donor is a haplo, plan is to give CD34 selected cells with some t cell add back. Read more
A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH ATEZOLIZUMAB WITH OR WITHOUT CARBOPLATIN AS FIRST-LINE INDUCTION OR MAINTENANCE, IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) Read more
A Multi-Center Phase II Randomized Trial of Immunotherapy versus Chemoimmunotherapy Guided by Circulating Tumor DNA Based Molecular Response on Patients with Metastatic NSCLC Read more
